Last reviewed · How we verify
Acthar
At a glance
| Generic name | Acthar |
|---|---|
| Also known as | Acthar Gel, H.P. Acthar Gel, Repository Corticotropin Injection, ACTH (Adrenocorticotropic hormone), repository corticotropin |
| Sponsor | Washington University School of Medicine |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Pharmacokinetic (PK), Pharmacodynamic (PD) and Tolerability of Osilodrostat in Pediatric Patients With Cushing's Syndrome (PHASE2)
- Use of Acthar in Patients With FSGS That Will be Undergoing Renal Transplantation (PHASE3)
- FET PET/CT Imaging To Localize Pituitary Adenomas In Cushing Disease (EARLY_PHASE1)
- A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer (PHASE2)
- AuriculoTherapy NeuroImaging (NA)
- CRF2 Agonist for the Treatment of Worsening Heart Failure (PHASE2)
- Use of Acthar in Rheumatoid Arthritis (RA) Related Flares (PHASE4)
- ACTH Stability on Whole Blood (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |